Rapid Tranquilization of Severely Agitated Patients With Schizophrenia Spectrum Disorders

被引:27
|
作者
Walther, Sebastian [1 ]
Moggi, Franz [1 ,2 ]
Horn, Helge [1 ]
Moskvitin, Konstantin [1 ]
Abderhalden, Christoph [1 ,3 ]
Maier, Nadja [1 ]
Strik, Werner [1 ]
Mueller, Thomas J. [1 ]
机构
[1] Univ Hosp Psychiat, CH-3000 Bern 10, Switzerland
[2] Univ Fribourg, Dept Psychol, CH-1700 Fribourg, Switzerland
[3] Univ Hosp Psychiat, Nursing & Social Educ Res Unit, CH-3000 Bern 10, Switzerland
关键词
aggressive behavior; agitation; schizophrenia; rapid tranquilization; haloperidol; risperidone; olanzapine; HALOPERIDOL PLUS PROMETHAZINE; INTRAMUSCULAR HALOPERIDOL; PSYCHOTIC AGITATION; ORAL RISPERIDONE; OLANZAPINE; VIOLENT; TRIAL; AGGRESSION; MANAGEMENT; LORAZEPAM;
D O I
10.1097/JCP.0000000000000050
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Agitation is a major problem in acute schizophrenia. Only a few studies have tested antipsychotic agents in severely agitated patients, mainly because of legal issues. Furthermore, most studies were limited to the first 24 hours. We aimed to investigate the efficacy of oral haloperidol, risperidone, and olanzapine in reducing psychotic agitation in severely agitated patients with schizophrenia or schizophreniform or schizoaffective disorder over 96 hours using a prospective, randomized, rater-blinded, controlled design within a naturalistic treatment regimen. Methods: In total, 43 severely agitated patients at acute care psychiatric units were enrolled. Participants were randomly assigned to receive either daily haloperidol 15 mg, olanzapine 20 mg, or risperidone 2 to 6 mg over 5 days. Positive and Negative Syndrome Scale psychotic agitation subscale score was the primary outcome variable. A mixed-model analysis was applied. Results: All drugs were effective for rapid tranquilization within 2 hours. Over 5 days, the course differed between agents (P < 0.001), but none was superior. Dropouts occurred only in the risperidone and olanzapine groups. Men responded better to treatment than did women during the initial 2 hours (P = 0.046) as well as over the 5-day course (P < 0.001). No difference between drug groups was observed regarding diazepam or biperiden use. Conclusions: Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders. Response to oral antipsychotics demonstrated a gender effect with poorer outcome in women throughout the study.
引用
收藏
页码:124 / 128
页数:5
相关论文
共 50 条
  • [21] Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice: Findings From the CLAMORS Study
    Bobes, Julio
    Arango, Celso
    Garcia-Garcia, Margarida
    Rejas, Javier
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (03) : 280 - 286
  • [22] Types of Thinking-Language Disorders in Patients with Schizophrenia Spectrum Disorders
    Smerchinskaya, Elina M.
    Tregubenko, Iliya A.
    Isaeva, Elena R.
    CLINICAL PSYCHOLOGY AND SPECIAL EDUCATION, 2024, 13 (02): : 147 - 158
  • [23] Movement disorders in neuroleptic-naive patients with schizophrenia spectrum disorders
    Ayehu, Moges
    Shibre, Teshome
    Milkias, Barkot
    Fekadu, Abebaw
    BMC PSYCHIATRY, 2014, 14
  • [24] The Care Needs of Elderly Patients With Schizophrenia Spectrum Disorders
    Meesters, Paul D.
    Comijs, Hannie C.
    Droes, Rose-Marie
    de Haan, Lieuwe
    Smit, Johannes H.
    Eikelenboom, Piet
    Beekman, Aartjan T. F.
    Stek, Max L.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2013, 21 (02) : 129 - 137
  • [25] REPRESENTATIONS OF THE PARENTAL FAMILY IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS
    Konovalova, A. H.
    Holmogorova, A. B.
    KONSULTATIVNAYA PSIKHOLOGIYA I PSIKHOTERAPIYA-COUNSELING PSYCHOLOGY AND PSYCHOTHERAPY, 2013, (01): : 90 - 113
  • [26] Neurocognitive function and mortality in patients with schizophrenia spectrum disorders
    Mohn, Christine
    Olsson, Anna-Karin
    Hard, Iris van Dijk
    Helldin, Lars
    SCHIZOPHRENIA RESEARCH-COGNITION, 2023, 33
  • [27] Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders
    Turczynski, J
    Bidzan, L
    Staszewska-Malys, E
    MEDICAL SCIENCE MONITOR, 2004, 10 (05): : PI74 - PI80
  • [28] Predictors of aggression in 3.322 patients with affective disorders and schizophrenia spectrum disorders evaluated in an emergency department setting
    Blanco, Emily A.
    Duque, Laura M.
    Rachamallu, Vivekananda
    Yuen, Eunice
    Kane, John M.
    Gallego, Juan A.
    SCHIZOPHRENIA RESEARCH, 2018, 195 : 136 - 141
  • [29] Dynamics of neurocognitive functioning in patients in early stages of schizophrenia and schizophrenia spectrum disorders
    Gurovich, I. Ya.
    Shmukler, A. B.
    Zaytseva, Yu. S.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2012, 112 (08) : 7 - 14
  • [30] Eating disorders and schizophrenia in male patients: A review
    Khalil, R. Bou
    Hachem, D.
    Richa, S.
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2011, 16 (03) : E150 - E156